Fig. 4.

Dasatinib, fluvastatin, and pazopanib sensitize YAP/TAZ-dependent cancer cells to doxorubicin and paclitaxel. (A) Combination therapy with doxorubicin and paclitaxel with (i) dasatinib, (ii) fluvastatin, or (iii) pazopanib. Cells were treated with dasatinib, fluvastatin, or pazopanib in combination with doxorubicin or paclitaxel for 4 days. Viability was measured by MTT assay. Data represents mean and standard deviation from triplicate, and data is representative of at least three independent experiments. ^*P < 0.02. N.S.: not significant. (B) Colony formation of MDA-MB-231 cells treated with dasatinib, fluvastatin, and pazopanib in combination with doxorubicin or paclitaxel. MDA-MB-231 cells were treated with the combination of inhibitors (dasa: dasatinib, fluva: fluvastatin, pazo: pazopanib, dox: doxorubicin, pac: paclitaxel) for 10 days. Colony formation was determined by staining with crystal violet. Data is representative of two independent experiments. (C) Effect of (i) dasatinib, (ii) fluvastatin, and (iii) pazopanib as chemosensitizers in MCF-7, YAP/TAZ-independent cell line. Viability was measured by MTT assay. Data represents mean and standard deviation from triplicate, and data is representative of at least two independent experiments. (D) Colony formation of MCF-7 cells treated with dasatinib, fluvastatin, and pazopanib in combination with doxorubicin or paclitaxel. MCF-7 cells were treated with the combination of inhibitors (dasa: dasatinib, fluva: fluvastatin, pazo: pazopanib, dox: doxorubicin, pac: paclitaxel) for 7 days. Colony formation was determined by staining with crystal violet. Data is representative of three independent experiments.